The Systemic Inflammation Response Index Efficiently Discriminates Between the Failure Patterns of Patients with Isocitrate Dehydrogenase Wild-Type Glioblastoma Following Radiochemotherapy with FLAIR-Based Gross Tumor Volume Delineation

Overview

Journal Brain Sci

Publisher MDPI

Date 2024 Sep 28

PMID 39335417

Authors

Sukran Senyurek

Murat Serhat Aygun

Nulifer Kilic Durankus

Eyub Yasar Akdemir

Duygu Sezen

Erkan Topkan

Yasemin Bolukbasi

Ugur Selek

Affiliations

Soon will be listed here.

Abstract

Background/objectives: The objective of this study was to assess the connection between the systemic inflammation response index (SIRI) values and failure patterns of patients with IDH wild-type glioblastoma (GB) who underwent radiotherapy (RT) with FLAIR-based gross tumor volume (GTV) delineation.

Methods: Seventy-one patients who received RT at a dose of 60 Gy to the GTV and 50 Gy to the clinical target volume (CTV) and had documented recurrence were retrospectively analyzed. Each patient's maximum distance of recurrence (MDR) from the GTV was documented in whichever plane it extended the farthest. The failure patterns were described as intra-GTV, in-CTV/out-GTV, distant, and intra-GTV and distant. For analytical purposes, the failure pattern was categorized into two groups, namely Group 1, intra-GTV or in-CTV/out-GTV, and Group 2, distant or intra-GTV and distant. The SIRI was calculated before surgery and corticosteroid administration. A receiver operating characteristic (ROC) curve analysis was used to determine the optimal SIRI cut-off that distinguishes between the different failure patterns.

Results: Failure occurred as follows: intra-GTV in 40 (56.3%), in-CTV/out-GTV in 4 (5.6%), distant in 18 (25.4%), and intra-GTV + distant in 9 (12.7%) patients. The mean MDR was 13.5 mm, and recurrent lesions extended beyond 15 mm in only seven patients. Patients with an SIRI score ≥ 3 demonstrated a significantly higher incidence of Group 1 failure patterns than their counterparts with an SIRI score < 3 (74.3% vs. 50.0%; = 0.035).

Conclusions: The present results show that using the SIRI with a cut-off value of ≥3 significantly predicts failure patterns. Additionally, the margin for the GTV can be safely reduced to 15 mm when using FLAIR-based target delineation in patients with GB.

References

Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R . Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 2011; 17(13):4296-308. DOI: 10.1158/1078-0432.CCR-10-2557. View

Jarmuzek P, Kozlowska K, Defort P, Kot M, Zembron-Lacny A . Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023; 15(13). PMC: 10340562. DOI: 10.3390/cancers15133339. View

Kruser T, Bosch W, Badiyan S, Bovi J, Ghia A, Kim M . NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol. 2019; 143(1):157-166. PMC: 6483830. DOI: 10.1007/s11060-019-03152-9. View

Wang Z, Li J, Yuan Y, Li T, Zuo M, Liu Y . Prognostic significance of preoperative systemic inflammation response index in newly diagnosed glioblastoma patients underwent gross total resection: a propensity score matching analysis. World J Surg Oncol. 2022; 20(1):137. PMC: 9052476. DOI: 10.1186/s12957-022-02588-0. View

Kinoshita M, Arita H, Okita Y, Kagawa N, Kishima H, Hashimoto N . Comparison of diffusion tensor imaging and C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. J Neurosurg. 2016; 125(5):1136-1142. DOI: 10.3171/2015.11.JNS151848. View

Sun C, Wang S, Ma Z, Zhou J, Ding Z, Yuan G . Neutrophils in glioma microenvironment: from immune function to immunotherapy. Front Immunol. 2024; 15:1393173. PMC: 11109384. DOI: 10.3389/fimmu.2024.1393173. View

Arbatskiy M, Balandin D, Churov A, Varachev V, Nikolaeva E, Mitrofanov A . Intratumoral Cell Heterogeneity in Patient-Derived Glioblastoma Cell Lines Revealed by Single-Cell RNA-Sequencing. Int J Mol Sci. 2024; 25(15). PMC: 11313325. DOI: 10.3390/ijms25158472. View

Zhang H, Ma L, Wang Q, Zheng X, Wu C, Xu B . Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. Eur J Radiol. 2014; 83(12):2181-2189. DOI: 10.1016/j.ejrad.2014.09.018. View

10.

Liang J, Piao Y, Holmes L, Fuller G, Henry V, Tiao N . Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2013; 20(1):187-98. PMC: 4422653. DOI: 10.1158/1078-0432.CCR-13-1279. View

11.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

12.

Fossati G, Ricevuti G, Edwards S, Walker C, Dalton A, Rossi M . Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999; 98(4):349-54. DOI: 10.1007/s004010051093. View

13.

Niyazi M, Brada M, Chalmers A, Combs S, Erridge S, Fiorentino A . ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol. 2016; 118(1):35-42. DOI: 10.1016/j.radonc.2015.12.003. View

14.

Ahmad N, Chen L, Yuan Z, Ma X, Yang X, Wang Y . Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway. Neurotherapeutics. 2024; 21(5):e00431. PMC: 11579875. DOI: 10.1016/j.neurot.2024.e00431. View

15.

Yilmaz M, Kahvecioglu A, Yedekci F, Yigit E, Ciftci G, Kertmen N . Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma. Neurooncol Pract. 2024; 11(3):275-283. PMC: 11085836. DOI: 10.1093/nop/npae009. View

16.

Tu Z, Xiong H, Qiu Y, Li G, Wang L, Peng S . Limited recurrence distance of glioblastoma under modern radiotherapy era. BMC Cancer. 2021; 21(1):720. PMC: 8218451. DOI: 10.1186/s12885-021-08467-3. View

17.

Topkan E, Besen A, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B . Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020; 2020:4392189. PMC: 7262659. DOI: 10.1155/2020/4392189. View

18.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

19.

Mizuhata M, Takamatsu S, Shibata S, Sakurai T, Minamikawa R, Yamazaki M . Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide. Jpn J Radiol. 2023; 41(6):660-668. DOI: 10.1007/s11604-023-01386-2. View

20.

Gebhardt B, Dobelbower M, Ennis W, Bag A, Markert J, Fiveash J . Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol. 2014; 9:130. PMC: 4055938. DOI: 10.1186/1748-717X-9-130. View